Proteomics in neurons and animals: substrates and therapeutic potential of alpha-and beta-secretase by unknown
ORAL PRESENTATION Open Access
Proteomics in neurons and animals: substrates
and therapeutic potential of alpha-and
beta-secretase
Stefan Lichtenthaler
From Molecular Neurodegeneration: Basic biology and disease pathways
Cannes, France. 10-12 September 2013
The aspartyl protease BACE1 is involved in myelination –
through neuregulin-1 cleavage - and is a major drug target
for Alzheimer’s disease, where it acts as the beta-secretase
cleaving the amyloid precursor protein. However, little is
known about other substrates in vivo. Recently, we and
others identified over 20 new BACE1 substrates in neu-
rons. To elucidate which of them are particularly relevant
in vivo, a comprehensive proteomic analysis of BACE1-
deficient mouse brains and CSF was carried out. A few
membrane proteins, including the cell adhesion proteins
CHL1 and contactin-2 as well as the APP protein family,
were identified as BACE1 substrates in vivo and point to a
central function of BACE1 in neurite outgrowth and
synapse formation. Validation of substrates and detailed
characterization of their cleavage was done in primary
neurons, CSF and mouse brains. Additionally, the new
substrates can be used as biomarkers for the efficacy and
potential side-effects of BACE1 inhibitors in clinical trials
of Alzheimer’s disease. Mechanistic analysis of substrate
cleavage suggests that BACE1 controls the cell surface
levels of its substrates and thus their function. Levels
of most other proteins were not significantly changed
in BACE1-/- brains, suggesting that therapeutic BACE1
inhibition is unlikely to lead to major proteome changes.
The talk will also present new substrates and functions for
ADAM10 in the brain.
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